Prelude Therapeutics Incorporated
PRLD
$3.94
$0.102.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 41.00% | 116.67% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 41.00% | 116.67% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 41.00% | 116.67% | -- | -- |
| SG&A Expenses | -10.95% | -21.17% | -34.21% | -16.26% | -16.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.80% | -42.67% | -27.98% | -13.37% | 0.77% |
| Operating Income | 59.03% | 52.56% | 40.60% | 13.37% | -0.77% |
| Income Before Tax | 67.63% | 42.72% | 38.88% | 10.10% | -2.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.63% | 42.72% | 38.88% | 10.10% | -2.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.63% | 42.72% | 38.88% | 10.10% | -2.08% |
| EBIT | 59.03% | 52.56% | 40.60% | 13.37% | -0.77% |
| EBITDA | 59.66% | 53.12% | 41.15% | 13.49% | -0.75% |
| EPS Basic | 70.20% | 45.47% | 39.09% | 10.36% | -1.73% |
| Normalized Basic EPS | 70.18% | 49.81% | 39.11% | 10.36% | -1.73% |
| EPS Diluted | 69.21% | 45.47% | 39.09% | 10.36% | -0.52% |
| Normalized Diluted EPS | 70.18% | 49.81% | 39.11% | 10.36% | -1.73% |
| Average Basic Shares Outstanding | 8.60% | 5.06% | 0.36% | 0.31% | 0.33% |
| Average Diluted Shares Outstanding | 8.60% | 5.06% | 0.36% | 0.31% | 0.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |